Key Takeaways
- The company reported a Q4 net loss of €305 million, a stark reversal from the €259.5 million profit recorded in the prior-year quarter
- 2026 revenue projections of €2–2.3 billion significantly missed analyst expectations of €2.75 billion
- CEO Ugur Sahin and CMO Ozlem Tureci, both company co-founders, will depart by the end of the year to establish a new biotech firm
- The German biotech will provide mRNA technologies to the founders’ new enterprise in return for a minority ownership position and royalty payments
- Declining demand for Covid-19 vaccines in both U.S. and European territories is projected to continue through 2026
BioNTech shareholders faced a perfect storm on Tuesday as the company simultaneously revealed quarterly losses, underwhelming future projections, and a major leadership transition. Shares plunged 17% during premarket hours, setting up BNTX for its steepest single-day decline since late 2021.
The biotechnology firm based in Germany disclosed a fourth-quarter net loss totaling €305 million. This represents a dramatic shift from the €259.5 million profit recorded during the corresponding quarter of the previous year. Quarterly revenues reached €907.4 million, marking a decline from the €1.19 billion generated a year earlier.
Breaking down the per-share metrics, BioNTech registered a loss of €1.25 for Q4. This result significantly underperformed analyst projections, which had anticipated a more modest loss of €0.45 per share.
The forward-looking guidance proved even more concerning for investors. Company leadership established 2026 revenue targets ranging from €2 billion to €2.3 billion. This forecast falls substantially short of the €2.75 billion figure that Wall Street analysts had projected — representing approximately a €450 million gap when comparing midpoints.
Declining sales of the Covid-19 vaccine represent the primary factor behind the revenue shortfall. Company executives indicated they anticipate reduced Comirnaty revenues throughout 2026 as vaccination demand continues to weaken in both American and European markets.
Revenue from the Bristol Myers Squibb cancer immunotherapy partnership is projected to remain “broadly in line with 2025,” providing minimal compensation for declining Covid vaccine sales.
Founding Leadership to Depart This Year
Adding to investor concerns was the leadership announcement. Ugur Sahin, serving as CEO, and Ozlem Tureci, the Chief Medical Officer — who are married and established BioNTech together in 2008 — revealed plans to exit the company before 2026 concludes to pursue a new mRNA-centered biotechnology venture.
The company’s supervisory board has initiated the process of identifying successor candidates.
According to the announcement, BioNTech intends to transfer “related rights and mRNA technologies” to the founders’ new startup, receiving in exchange a minority equity position, performance-based milestone payments, and revenue-sharing arrangements. Both organizations will maintain independent operational resources and financing structures.
Sahin and Tureci elevated BioNTech to global recognition throughout the Covid-19 pandemic, when their groundbreaking mRNA research enabled the development of the Comirnaty vaccine in partnership with Pfizer.
Increased Scrutiny on mRNA Technology
The stock has also contended with heightened regulatory challenges within the United States. mRNA-based platforms have encountered growing examination following Robert F. Kennedy Jr.’s appointment as Secretary of Health and Human Services. The present administration has demonstrated considerable skepticism toward mRNA vaccination technology.
Prior to Tuesday’s market decline, BNTX shares had appreciated 7.3% in 2026. Pfizer, its Comirnaty collaboration partner, had recorded gains of 7.7% during the identical timeframe.
For comparative perspective, Moderna had surged 89% and Novavax had climbed 57% entering Tuesday’s session — both substantially outperforming their larger industry competitors.
BioNTech’s projected adjusted research and development expenditures for 2026 fall within a range of €2.2 billion to €2.5 billion, demonstrating continued commitment to advancing its oncology product portfolio.
Management stated expectations to operate 15 advanced-stage oncology clinical trials by the conclusion of this year, establishing a strategic objective of evolving into a diversified multi-product organization by 2030.
BioNTech’s American depository receipts were changing hands at $84.59 during Tuesday morning’s premarket session, representing a 17% decline for the trading day.
